Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Recordati announced today that it has completed the acquisition of EUSA Pharma, a private specialty pharmaceutical company focused on oncology and rare…
Italy's Recordati is shelling out $845 million to acquire UK-based rare-cancer specialist EUSA Pharma from EW Healthcare Partners. The deal adds four marketed…
Recordati FY2024: Rare Diseases revenue EUR 833.9M (+16.7%); Hema-Oncology franchise (Qarziba + Sylvant) EUR 253.2M with double-digit growth from both…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Recordati closed acquisition of EUSA Pharma for ~$845M (€750M enterprise value), adding four rare-cancer products: Qarziba (anti-GD2 mAb in neuroblastoma), Sylvant (anti-IL-6 mAb in Castleman disease), Fotivda (TKI in RCC), and Caphosol (oral mucositis). Closed March 16, 2022.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Recordati S.p.A. / EUSA Pharma (UK) Ltd. (this deal) | 2022 | $845M | — |
| Recordati S.p.A. / Sanofi SA | 2024 | $1.1B | — |
| Recordati S.p.A. / Ionis Pharmaceuticals, Inc. | 2026 | — | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
← Browse all deals · How we score deals
More: 2022 deals · Recordati S.p.A. deals · Neurology deals